A record of what Amit Khurana said publicly, with the source. Not advice.
Pending — not yet graded
“Amit Khurana views Sun Pharma's recent acquisition as strategically sound and directionally correct for long-term growth, particularly in biosimilars, considering the equity valuation reasonable. While the nearly $10 billion debt component is a significant concern that requires careful navigation, he believes it is largely manageable if execution and product scalability remain on track over the next few years.”
Sun PharmaBullishCalled 27 Apr 2026
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Amit Khurana’s full track record